Podcasts about Ipsen

In this episode of Liver Lineup: Updates & Unfiltered Insights, hosts Kimberly Brown, MD, a professor of Medicine at Michigan State University and Wayne State University, associate medical director of the Henry Ford Hospital Transplant Institute, and medical director of Transplant Outreach Services at Henry Ford Hospital, and Nancy Reau, MD, a professor of internal medicine, the Richard B. Capps Chair of Hepatology, associate director of solid organ transplantation, and the section chief of hepatology at Rush University Medical Center, highlight 4 key abstracts presented at the 2025 European Association for the Study of the Liver (EASL) Congress. Key Episode Timestamps 00:00:01 Introduction 00:00:45 Efimosfermin Alfa in MASH 00:05:56 PEth Testing 00:13:19 RETRACT-B 00:20:44 Linerixibat in PBC Relevant Disclosures for Reau include AbbVie, Gilead, Salix, Arbutus, and VIR. Relevant disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal.

In this episode of Liver Lineup: Updates & Unfiltered Insights, hosts Kimberly Brown, MD, a professor of Medicine at Michigan State University and Wayne State University, associate medical director of the Henry Ford Hospital Transplant Institute, and medical director of Transplant Outreach Services at Henry Ford Hospital, and Nancy Reau, MD, a professor of internal medicine, the Richard B. Capps Chair of Hepatology, associate director of solid organ transplantation, and the section chief of hepatology at Rush University Medical Center, continue their discussion on notable abstracts presented at the 2025 European Association for the Study of the Liver (EASL) Congress. If you haven't already, be sure to check out part 1 here! Key Episode Timestamps 0:00:00 LITMUS Study 0:05:47 Norursodeoxycholic Acid in PSC 0:10:12 GLOBE Score for PBC 0:15:11 Conclusion Arbutus, and VIR. Relevant disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal.

Concluding their three-episode series filmed live in Chicago, your hosts wrap up the weekend with a discussion of the key bladder cancer presentations from the 2025 ASCO Annual Meeting. They begin in the perioperative space, reviewing updated CREST data presented since AUA and revisiting the NIAGARA trial last seen at ESMO 2024, and end by covering the latest EV-302 updates in the metastatic setting.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

Picking up from Episode 23, your hosts turn their focus to the highly anticipated prostate cancer presentations from the 2025 ASCO Annual Meeting in Chicago. They begin with a discussion on mCSPC, focusing on the AMPLITUDE trial, followed by results from TALAPRO-2, the ARANOTE trial, IRONMAN, and STAMPEDE. The episode wraps with key abstracts and oral presentations on mCRPC.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

Recorded live in Chicago, your hosts explore the latest in kidney cancer, discussing new five-year follow-up data from KEYNOTE-564, the long-term results of CheckMate 214, insights from the ongoing PDIGREE trial, and much more.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

Welche Bestseller lohnen sich wirklich? Karla und Günter verraten es euch.Zweimal im Jahr lesen sich Karla und Günter durch die Bestseller-Listen und schauen, ob echte Perlen darunter sind. In dieser Folge empfehlen die beiden sechs Romane, die sich wunderbar als Strandkorb-Lektüre eignen. Die 17-jährige Morlen reist nach LA, um dort auf Heathers Kinder aufzupassen. Die Freundin ihrer Mutter ist unglücklich in ihrer Ehe und heilfroh über Morlens Unterstützung. Meike Werkmeister erzählt in „Über den Wolken wohnen die Träume” von zwei ungleichen Frauen, die ihr Glück suchen. Kommissar Lennart Ipsen arbeitet dort, wo andere Urlaub machen: auf der Insel Bornholm. Plötzlich erschüttert ein Mord die Idylle, und Ipsen ermittelt. Michael Kobrs Roman „Schatten über Sømarken“ ist beste Krimi-Unterhaltung mit viel dänischer Kulinarik. Was passiert, wenn Menschen Zeit geschenkt bekommen? In dem Roman von Maja Lunde „Für immer” stirbt niemand und niemand wird mehr geboren. Ein spannendes Gedankenexperiment, das noch lange nachhallt. Volker Klüpfel erzählt in seinem Roman „Wenn Ende gut, dann alles“ den ersten Fall des eigenwilligen Ermittlerduos Tommi und Svetlana. Er ist ein erfolgloser Drehbuchautor, und sie macht bei ihm sauber. Als die beiden ein kleines Mädchen am Waldrand auflesen, geraten sie auf der Suche nach der Mutter in große Gefahr. Als „charmanten Unfug” bezeichnete der NDR das neue Buch von Jonas Jonasson “Wie die Schweden das Träumen erfanden”. Darin versucht die schwedische Bürgermeisterin Julia das deutsche Unternehmen Traumbett an ihrem Ort anzusiedeln – mit äußerst skurrilen Methoden. Das „Ministerium der Zeit” holt Menschen aus früheren Jahrhunderten mit einer Zeitmaschine in die Gegenwart. So auch den Polarforscher Graham. Zusammen mit seiner Betreuerin entdeckt er das 21. Jahrhundert und stellt fest, dass früher manches besser war... Die Bücher in dieser Folge:Meike Werkmeister: „Über den Wolken wohnen die Träume“ (Goldmann) Michael Kobr: „Schatten über Sømarken“ (Goldmann) Maja Lunde: „Für immer“ (btb) Volker Klüpfel: „Wenn Ende gut, dann alles“ (Penguin) Jonas Jonasson: „Wie die Schweden das Träumen erfanden“ (C. Bertelsmann) Kaliane Bradley: „Das Ministerium der Zeit“ (Penguin) +++ Viel Spaß mit dieser Folge. Wir freuen uns auf euer Feedback an podcast@penguinrandomhouse.de!” +++ Unsere allgemeinen Datenschutzrichtlinien finden Sie unter https://art19.com/privacy. Die Datenschutzrichtlinien für Kalifornien sind unter https://art19.com/privacy#do-not-sell-my-info abrufbar.

German is a practitioner of "mixed cognitive arts" building modern brands across a full spectrum of categories (with a leaning toward health, pharma, wellness, beauty, finance, insurance, food, hospitality, sports and automotive).A Silicon Valley-trained entrepreneur and thought leader applying ingenuity and leading methodologies to simplify marketing challenges using human insights, cultural trends, lateral thinking and new technologies.A passionate advocate for anthropology bringing ethnographies, artificial intelligence, expert crowdsourcing and cultural computing to advertising, media, innovation and corporate strategy. A client-savvy executive building long-lasting client relationships and driving high-profile pitch wins and account retention for agencies.A visionary team architect mentoring talent, rejuvenating culture and shaping the future of the Strategy & Planning discipline.Feeling at home in both disruptive and mainstream agencies with a preference for the former.Brands: Procter & Gamble, Unilever, Intel, NASDAQ, Ask.com, Creditcards.com, Ely Lilly, AMGEN, Novartis, Pfizer, Otsuka, Kyowa Kirin, Ipsen, Stryker, Foundation Medicine, National Jewish Health, Weight Watchers, Bank of America/Merrill Lynch, American Family Insurance, Emblem Insurance, Volvo, Volkswagen, Honda, Lufthansa, Expedia, L'Oreal, Estee Lauder, Erno Laszlo, Victoria's Secret, RadioShack, Best Buy, CVS, Burger King, Domino's Pizza, Wendy's, Miller Coors, Brown Forman, Kahlua, Nike, Pearl Izumi.

In dieser Folge von Thores Tea Time Tour treffe ich Doris Ipsen, die neue Geschäftsführerin des Unternehmensverbands Unterelbe-Westküste (UVUW), in Husum.​ Im Gespräch erfahren wir mehr über: die Aufgaben und Ziele des UVUW als Lobbyverband für die regionale Wirtschaft,​ die Rolle von Doris Ipsen als Geschäftsführerin und ihre Vision für die Unternehmerwelt in der Region,​ die Herausforderungen und Chancen, die sich durch aktuelle wirtschaftliche Entwicklungen ergeben,​ und wie der UVUW Unternehmen in Zeiten des Wandels unterstützt.​ Mindestlohn, Frauenquote und Northvolt

This educational program, hosted by Patrick McKiernan, MD, Pediatric Hepatologist at Birmingham Children's Hospital NHS Foundation Trust and Nadia Ovchinsky, MD, Professor of Medicine at NYU Grossman School of Medicine discuss the recently published guidance on best practices to diagnose, treat, and monitor patients with PFIC. It also explains why the new guidance recommends the early use of IBAT inhibitors in patients suspected of having progressive familial intrahepatic cholestasis (PFIC).PFIC encompasses a spectrum of autosomal recessive disorders characterized by impaired bile flow (cholestasis) due to defects in biliary epithelial transporters. These rare genetic conditions typically manifest in infancy or early childhood, leading to severe liver dysfunction and potentially life-threatening complications if left untreated. Common early symptoms observed in children with PFIC are jaundice, pruritus, elevated serum bile acid (SBA) values, malabsorption, and failure to thrive. PFIC can be a debilitating condition that significantly impacts the quality of life and can result in end-stage liver disease. As such, early detection and effective intervention are imperative for the prevention of disease progression. Unfortunately, there are no relevant guidelines based on newly published research to help healthcare providers manage patients with PFIC. However, a recent opinion paper by leading experts in the management of PFIC provides evidence-based guidance on this subject and was recently published in JHEP Reports. This educational program is made possible by an unrestricted grant from Ipsen.

Didier Hameau fait le point sur la baisse du CAC 40 après deux séances de forte hausse. Les résultats trimestriels décevants de certaines entreprises comme Katana, Ipsen et la FDJ ont pesé sur la tendance.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Didier Hameau fait le point sur la baisse du CAC 40 après deux séances de forte hausse. Les résultats trimestriels décevants de certaines entreprises comme Katana, Ipsen et la FDJ ont pesé sur la tendance.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Join Isabel and Jade as they wrap up Season 9 of the podcast with special guest Dennise Broderick, President and Managing Director, Galen Pharma.  In this episode, Jade and Dennise discuss her move from academia to the pharmaceutical industry, her lifelong ambition to be a leader and how she approaches hard decisions in business.  A little more on EMJ GOLD's guest… Dennise is Managing Director and President at Galen – a pharmaceutical company based in Northern Ireland focused on pain management, dermatology and gastroenterology. There, she is responsible for all the aspects of the company's operations, marketing and governance across its various sites throughout the UK and Europe. Previously, Dennise has held positions at Pfizer, Hospira, Zeneus and Viatris – most recently working as the Country Manager at Ipsen. 

In this EASL DeepDive held on 03 July 2024, Palak Trivedi, Emma Culver, Andreas Kremer and Jessica Dyson explain the risk assessment in people with PBC as well as the mechanistic and treatment of fatigue and pruritus.Learning objectivesDiscover the latest mechanistic insights relating to the occurrence of PBC symptomsLearn more about the holistic management of PBC symptoms, with a particular emphasis on fatigue and pruritusLearn more about the current treatment options, their efficacy and limitationsGet a detailed understanding of the drugs in the pipeline for the near futureThis EASL DeepDive webinar is supported by GSK and IPSEN. GSK and IPSEN have had no input into the content of this EASL DeepDive.Click here to see all EASL Video Podcasts on Apple Podcasts.

Dr. Tania Small joined Bristol Myers Squibb as Senior Vice President, Global Medical Affairs in January 2024. Tania brings a strong scientific track record leading Medical Affairs teams in driving innovation that improves the experience and supports better outcomes of people living with cancer and rare diseases. She has successfully built and led global and regional medical organizations in Drug Development and Medical Affairs, advancing access to Oncology, Rare Disease and Hematology patients globally.Tania is a board-certified pediatric hematology, oncology, and bone marrow transplant specialist with deep experience in clinical research and drug development. She has extensive research experience in oncology, hematology, gene therapy and stem cell transplantation, receiving NIH grants for her translational research in gene therapy and regenerative medicine.Most recently, Tania served as Head of Global Medical Oncology and was the sponsor of the Global R&D Inclusion Diversity Council at GSK. Prior to GSK, Tania worked for IPSEN as Vice President, Head of Oncology and Rare Disease Global Drug Development.She is energized by revolutionizing the experience and outcomes for people with cancer, and has worked closely with the US FDA, Congress, and the American Society of Clinical Oncology (ASCO) to improve the diversity of enrollment in oncology clinical trials and elderly programs."I'm passionate about partnering to create programs that treat the person - not just the disease. Producing groundbreaking solutions that can change the trajectory of serious diseases and help write the next chapter of patient-driven science is what motivates me every day."Tania received her medical degree from Albert Einstein College of Medicine. She has a long-standing affiliation with the Morgan Stanley Children's Hospital of New York Presbyterian/Columbia University where she completed her residency and hematology/oncology fellowship with an academic research appointment in heme and bone marrow transplant.Currently, Tania serves on the ASCO Membership Advisory Committee and is a Board Member of Accreditation Council for Medical Affairs (ACMA).

In deze podcast, u aangeboden door Astellas Pharma B.V., spreekt internist-oncoloog Koos van der Hoeven met internist-oncoloog Cheryl Bruijnen, UMC Utrecht, en cardioloog Anne van Schijndel, Antoni van Leeuwenhoek te Amsterdam, over de aandacht voor cardiovasculaire bijwerkingen van uiteenlopende oncologische behandelingen. Aan bod komen onder andere de verschillende middelen die cardiotoxiciteit kunnen veroorzaken, de impact van cardiotoxiciteit, de achterliggende pathologische mechanismen, de kenmerken en comorbiditeiten van de patiënt en hoe om te gaan met cardiotoxiciteit. Referenties 1. Herrmann J. Nat Rev Cardiol 2020;17:474-502. 2. Cardinale D, et al. Front Cardiovasc Med 2020;7:26. 3. Bloom MW, et al. Circ Heart Fail 2016;9:e002661. 4. Lyon AR, et al. Eur Heart J 2022;43:4229-361. 5. Dempsey N, et al. Breast Cancer Res Treat 2021;188:21-36. 6. Ewer MS, et al. Nat Rev Cardiol 2015;12:547-58. 7. Omland T, et al. JACC CardioOncol 2022;4:19-37. 8. Wu Q, et al. Cardiovasc Drugs Ther 2022;36:511-24. 9. Shiga T, et al. Curr Treat Options Oncol 2020;21:27. 10. Saif MW. Onco Targets Ther 2020;13:10197-206.Disclosures Dr. Cheryl Bruijnen: Astellas B.V., advisory boards Ipsen, Johnson & Johnson en MSD, speakers fee Ipsen, Johnson & Johnson en Novartis. Drs. Anne van Schijndel: Astellas B.V. en Philips. Prof. dr. ir. Koos van der Hoeven: Astellas, Bayer, BMS, Daiichi Sankyo, Gilead, Novartis, Pfizer, Seagen, lid Adviescollege VIG en lid RVT DICA.Podcast: MAT-NL-NON-2025-00013 FEB 2025Website: MAT-NL-NON-2025-00015 FEB 2025

'One FM' by One MSL strives to connect voices within the global Field Medical community. For the launch episode of One FM, Helen was joined by Sian Carr, Global Head of Training and Capabilities, Medical Excellence at Ipsen. If you would like to feature on a future episode, please email community@onemsl.com https://www.onemsl.com/

2025-01-26 - Guds rige er for børn, Mark 10,13-16, v. Andreas Ipsen by

Curious to discover what might lie ahead for industry in 2025? Join Isabel and Jade in this special episode of the EMJ GOLD podcast as they reflect on whether last year's predictions for 2024 came true, while three special guests share their predictions and hopes for pharma in the year ahead.  The line-up includes Jennifer Schranz of Ipsen, Mercedes Diz of Almirall and EMJ's own Dr Jonathan Sackier - all of whom share their predictions in their areas of expertise.  A little more on GOLD's guests…  Jennifer Schranz is the Senior Vice President, Global Head of Rare Diseases at Ipsen, where she oversees the Rare Diseases therapy area with a focus on R&D strategy and execution. During her time at the business, she has led talented teams of scientists and fostered strong internal collaborations within the company, leveraging her clinical development expertise to advance Ipsen's vision of addressing challenging rare diseases.  Mercedes Diz has over 20 years' experience in the pharmaceutical industry, having graduated with a degree in Biochemistry and Molecular Biology from the Autonomous University of Madrid. She has worked in a number of different pharmaceutical companies, from J&J to Pfizer, and is also a keen member of the Healthcare Businesswomen's Association. At Almirall, she leads portfolio strategy and commercial innovation for global brands, new products and digital and cultural transformation.  Dr Jonathan Sackier is Chairman at EMJ and the host of the EMJ podcast, where he utilises his experience as a physician to discuss the latest breakthroughs and challenges in the medical field with fellow practitioners and experts. Jonathan is a founding partner of many start-ups in the medical technology space and created the world's first operating room robot. 

For women with rare diseases, they often face a double jeopardy, where many of the symptoms they experience can be confused with and misdiagnosed as menopause. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jennifer Schranz, head of rare diseases at Ipsen, for a conversation focused on rare liver disease primary biliary cholangitis (PBC), which affects nine women for every one man, and the women's health gap more generally. Schranz explains the importance of developing a more individualised approach to management and treatment of PBC for each patient and discusses Ipsen's PBC therapy Iqirvo (elafibranor). You can listen to episode 162a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!

As 2024 comes to a close, it's time to look back on a year in the pharmaceutical industry. In this final episode of the year, Isabel and Jade are joined by three former guest to reflect on the pivotal moments that defined the past 12 months. They are joined by Jennifer Schranz from Ipsen, Martina Dempsey from Astellas and Elias Revonta, CEO of Orcason, who all return to the podcast to share their insights. Together, they'll discuss the major trends, challenges and breakthroughs that shaped 2024, including advancements in oncology, gene therapy, rare diseases and the growing role of AI. A little more on EMJ GOLD's guests... Jennifer Schranz is the Senior Vice President, Global Head of Rare Diseases at Ipsen, where she oversees the Rare Diseases therapy area with a focus on R&D strategy and execution. During her time at the business she has led talented teams of scientists and fostered strong internal collaborations within the company, leveraging her clinical development expertise to advance Ipsen's vision of addressing challenging rare diseases. Martina Dempsey is the Vice President of Commercial Strategy & Operations at Astellas Europe, having worked with the business since 2014 in her home country of Ireland. In addition to her role at the pharma company, she also acts as a Board Member for the Irish Pharmaceutical Healthcare Association. Prior to her time at Astellas, she spent 13 years at GSK in various roles including in the regulatory affairs and business transformation sectors. Elias Revonta is the Founder and CEO, Orcason Medical, where he is supported by a strong background in the medical device industry – spanning over 20 years in various leadership roles from sales to product development. He is passionate about transforming and democratising healthcare with modern and easy-to-use diagnostic tools that serve all demographics.

“The Leadership Development Committee (LDC) is one of the most important member volunteer positions in the organization, and here's why: The main purpose of the LDC is to recruit, vet, and select ONS Board of Directors. As some of you may know, it has been three years since we moved away from members voting for directors,” ONS member Nancy Houlihan, MA, RN, AOCN®, ONS past president and former director of nursing practice at Memorial Sloan Kettering Cancer Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about what it's like to serve on the Leadership Development Committee.  The advertising messages in this podcast episode are paid for by Ipsen.    Music Credit: “Fireflies and Stardust” by Kevin MacLeod   Licensed under Creative Commons by Attribution 3.0   Episode Notes   This episode is not eligible for NCPD.  Oncology Nursing Podcast™ episodes:  Episode 340: What It's Like to Plan an ONS Conference  Episode 337: Meet the ONS Board of Directors: Haynes, Wilson, and Yackzan  Episode 270: Meet the ONS Board of Directors: Brown, MacIntyre, and Woods  Episode 239: Meet the ONS Board of Directors: Allen, Mathey, and Robison  Episode 224: Meet the ONS Board of Directors: Nevidjon, Geddie, and Garner  Episode 213: Meet the ONS Board of Directors: Brant, Burger, and Knoop  Episode 200: Meet the ONS Board of Directors: Houlihan, Ferguson, and Polovich  ONS Voice articles:  Find Your Voice With ONS's Leadership Development Committee  Nursing Leadership Unlocked  Nurses Empower Change Through Leadership and Advocacy Roles  Think Tank Will Explore Nurse Leadership Development Initiatives  ONS course: Board Leadership: Nurses in Governance  ONS Volunteer Opportunities   ONS Leadership Learning Library  Contact the LDC  To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an Oncology Nursing Podcast™ Club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From This Episode “I feel like I have come full circle, developing my knowledge and leadership skills over 25 years, both at ONS and in my professional career, applying them to ONS leadership as a director and an officer, and then transferring that knowledge to work with a diverse team of ONS members on the LDC to build the best slate of directors.” TS 3:52  “There's an annual review and editing of processes based on experience and discussion with board leadership and a review of the [notification of intent] and full applications of candidates for the board of directors. As you can imagine, reviewing the notifications of intent packages and the full applications, references, and interviews is very time consuming and requires significant at home and meeting time to complete. The application process is rigorous. The LDC members are the stewards of that work, ensuring fairness and ending with the best possible board of directors.” TS 6:22  Each member of the LDC recognizes the importance of their role in identifying future leaders. They regularly interact with chapter members and leaders and others to relay the opportunities and processes for leadership roles, as I mentioned already, the LDC annually offers Round Table sessions at Congress and bridge. They are advertised to appeal to nurses with an interest in leadership in general, as well as at ONS.” TS 8:28  “An important component to this role is meeting the diversity needs on the board, and every effort is made to ensure that our net is cast wide and is inclusive, while the skill set for board service is at a higher level, we uphold ONS principles relative to belonging and look for an inclusive compliment of directors.” TS 9:33  “Frequently, the LDC works with qualified candidates who opt to wait to move forward because of work commitments, graduate school demands, or family concerns and come back when their lives are more settled, enough to take on the commitments of ONS. Support of employers is a required part of the application for the LDC and the board of directors, since time away from work can be challenging. However, many employees see ONS affiliation as a positive for their organization and are willing to engage in discussions with you about how to make a leadership role possible with your work responsibilities.”  TS 10:28  “Historically, there has been a misconception that you can't ‘break into ONS leadership.' I have served the last four years, and my experience has been that we are always looking for new qualified thought leaders from every possible group that ONS serves. For example, we track what worksites our leaders come from so that we have every subspecialty's voice over time.” TS 16:27   “Bottom line is, ONS needs you. Don't be shy to try. The door is open to discuss, and the right opportunity could be available.” TS 17:00  “I am constantly reminded about how smart and influential nurses are and how much they have to contribute. Working with an organization like ONS that unites you with others around a common purpose is very powerful.” TS 17:15   “You know, ONS needs leaders; we're always looking to talk with people about what their interests and strengths are and how they can develop some of those strengths through various volunteer activities.” TS 18:39 

Send us a textLaura K. Ipsen is president and chief executive officer of Ellucian, the leading technology solutions provider for more than 2,900 higher education institutions in more than 50 countries. She has more than 25 years of experience as a technology executive in Silicon Valley, driving transformation in the public and private sectors and spurring adoption of comprehensive solutions in high-growth industries at Oracle Corporation, Microsoft and Cisco Systems. Earlier in her career, Ipsen also held leadership roles at PricewaterhouseCoopers, Acer America, and Hitachi Data Systems.

O acidente vascular cerebral (AVC) é a segunda principal causa de mortes no Brasil e uma das doenças mais incapacitantes no mundo. Para os pacientes que sobrevivem, há um novo desafio: o da reabilitação. Neste episódio especial do DrauzioCast, o dr. Drauzio Varella media uma roda de conversa para explicar como é a jornada de reabilitação de pacientes que tiveram AVC e a importância de uma equipe multidisciplinar para uma recuperação adequada. Os participantes da roda são o Dr. Eduardo Rocha, que é Médico Fisiatra, ex-Presidente da Associação Brasileira de Medicina Física e Reabilitação (ABMFR), a Dra. Carolina Souza, Médica Neurologista, especialista em distúrbios do movimento e cognição, o Prof. Guilherme Herrera – Fisioterapeuta especialista em fisioterapia neurológica e Fátima Viscarra, Cuidadora e Esposa do Rui Martins, que sofreu um AVC aos 36 anos.Esta iniciativa visa promover a conscientização sobre o AVC. Trata-se de um programa exclusivamente educacional sobre a doença.Conteúdo produzido em parceria com Caminhos Pós AVC, uma iniciativa da Ipsen farmacêutica.Out/24 | ALLSC-BR-000490Veja também: Por que os casos de AVC têm crescido entre os mais jovens?

In this new episode, the team welcomes Jennifer Schranz, Senior Vice President, Global Head of Rare Diseases, Ipsen, to investigate the burden faced by women with rare diseases. Together, Jennifer and Jade discuss how the industry can address challenging rare diseases and making a meaningful impact on patients' lives, the double jeopardy that women with rare diseases face, recent breakthroughs in the space and much more.

On the eve of Thursday night's 21st MM+M Awards gala, Marc Iskowitz interviews jury chair Eduardo Molina, VP business operations and strategy at Ipsen, for his sneak peek on this year's standout work, and trends to watch out for during a star-studded evening.Music by Sixième Son  Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Wrapping up their ESMO Congress 2024 coverage with a discussion of renal cancer, our hosts talk about what strategies work (or don't) after frontline therapy for mRCC, implications on adjuvant therapy, as well as major efforts for non-clear cell histologies like the SUNNIFORECAST trial. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, J&J Innovative Medicine, Merck, Novartis, Pfizer, TerSera.

In the second episode of our ESMO Congress 2024 series, our hosts discuss both non-muscle invasive and muscle-invasive bladder cancer, along with other data that impacts the spectrum of urothelial cancer diagnosis and treatment.  The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, J&J Innovative Medicine, Merck, Novartis, Pfizer, TerSera.

In the first episode of this three-part series focused on the presentations and findings from the ESMO Congress 2024, our hosts focus on mCSPC prostate cancer treatment advancements, including lutetium PSMA, darolutamide and much more. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, J&J Innovative Medicine, Merck, Novartis, Pfizer, TerSera.

Dr. Shaalan Beg and Dr. Arturo Loaiza-Bonilla discuss the potential of artificial intelligence to assist with patient recruitment and clinical trial matching using real-world data and next-generation sequencing results. TRANSCRIPT Dr. Shaalan Beg: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Shaalan Beg, your guest host for the podcast today. I'm an adjunct associate professor at UT Southwestern's Simmons Comprehensive Cancer Center in Dallas and senior advisor for clinical research at the National Cancer Institute. On today's episode, we will be discussing the promise of artificial intelligence to improve patient recruitment in clinical trials and advanced clinical research. Joining me for this discussion is Dr. Arturo Loaiza-Bonilla, the medical director of oncology research at Capital Health in Philadelphia. He's also the co-founder and chief medical officer at Massive Bio, an AI-driven platform that matches patients with clinical trials and novel therapies.  Our full disclosures are available in the transcript of this episode.   Arturo, it's great to have you on the podcast today.  Dr. Arturo Loaiza-Bonilla: Thanks so much, Shaalan. It's great to be here and talking to you today.  Dr. Shaalan Beg: So we're all familiar with the limitations and inefficiencies in patient recruitment for clinical trials, but there are exciting new technologies that are addressing these challenges. Your group developed a first-in-class, AI-enabled matching system that's designed to automate and expedite processes using real-world data and integrating next-generation sequencing results into the algorithm. You presented work at the ASCO Annual Meeting this year where you showed the benefits of AI and NGS in clinical trial matching and you reported about a twofold increase in potential patient eligibility for trials. Can you tell us more about this study?  Dr. Arturo Loaiza-Bonilla: Absolutely. And this is just part of the work that we have seen over the last several years, trying to overcome challenges that are coming because of all these, as you mentioned, inefficiencies and limitations, particularly in the manual patient trial matching. This is very time consuming, as all of us know; many of those in the audience as well experience it on a daily basis, and it's resource intensive. It takes specialized folks who are able to understand the nuances in oncology, and it takes, on average, even for the most experienced research coordinator or principal investigator oncologist, 25 minutes per trial. Not only on top of that, but in compound there's a lack of comprehensive genomic testing, NGS, and that complicates the process in terms of inability to know what patients are eligible for, and it can delay also the process even further.  So, to address those issues, we at Massive Bio are working with other institutions, and we're part of this … called the Precision Cancer Consortium, which is a combination of 7 of the top 20 top pharma companies in oncology, and we got them together. And let's say, okay, the only way to show something that is going to work at scale is people have to remove their silos and barriers and work as a collaborative approach. If we're going to be able to get folks tested more often and in more patients, assess for clinical trials, at least as an option, we need to understand further the data. And after a bunch of efforts that happened, and you're also seeing those efforts in CancerX and other things that we're working on together, but what we realize here is using an AI-enabled matching system to basically automate and expedite the process using what we call real-world data, which is basically data from patients that are actually currently being treated, and integrating any NGS results and comparing that to what we can potentially do manually. The idea was to do multi-trial matching, because if we do it for one study, yeah, it will be interesting, but it will not show the potential applicability in the real world.  So with all that background, the tool itself, just to give you the punchline of it, was proven highly effective in terms of efficiency. We were able to increase the number of potential matches, and not only that, but reducing the time to the matching. So basically, instead of spending 25 minutes, it could be done in a matter of seconds. And when you compound all that across multiple clinical trials, in this case, it was several sponsors coming together, we were able to reduce the manual effort of seeing patients and testing for clinical trials to basically 1 hour when it would have otherwise taken a ridiculous amount of time. And it was quantified as 19,500 hours of manual work, compared to 1 hour done by the system to uniquely match a cohort of about 5,600 patients that came into the platform. And this was across 23 trials. Now imagine if we can do it for the 14,000 clinical trials currently in clinicaltrials.gov.   So for us, this kind of was an eye-opening situation that if we can increase not only the efficiency but find even more trials by integrating comprehensive genomic testing, which in this case was a twofold increase in eligibility for clinical trials, that gives us not only the opportunity for optimized processes using AI but also a call to action that there is still a lot of under-genotyping. And I know American Cancer Society and ASCO and many others are working hard on getting that into fruition, but we need to have systems that remind us that certain patients are not tested yet and that can improve not only real patients, but the R&D and the process of innovation in the future. Dr. Shaalan Beg: Yeah, it's always an important reminder that even some of the highest impact IT solutions or AI solutions are most effective if they can be integrated into our normal clinical processes and into the normal workflow that we have in our clinics to help clinicians do their work quickly and more efficiently. Can you talk about how, over the last few years, the availability of NGS data in our electronic medical record (EMR) has evolved and whether that's evolving for the better? And what are some next steps in terms of making that data available at EMR so that such solutions can then pull that data out and do clinical trial matching?  Dr. Arturo Loaiza-Bonilla: Yes. So one of the things that we have seen over the last couple of years is because of the applicability of the 21st Century Cures Act, there is less “information blocking,” which is patients not being able to access their information in real time. Now, with the appearance of health exchanges, with patient-centric approaches, which is something that many innovators, including ours, are trying to apply, it's really becoming more relevant. So it's not only helping us to find the patients when they really need to get tested, but also is giving us the opportunity to put those patients into the right treatment pathway when found. Something that's still a challenge and I think we can work by being more collaborative once again – is my dream – is having these pre-screening hubs where no matter where you are in your cancer journey, you just go into that funnel and then are able to see, “Okay, you are in the second-line setting for non-small cell lung cancer, EGFR-mutated. Now, do you have a meta amplification, then you go for this study or this trial. Oh, you haven't been tested yet. You should get tested. You're a pancreas cancer patient who is KRAS wild type; well, there is a significant chance that you may have a biomarker because that's where most patients are enriched for.” So having that opportunity to at scale, just for the whole country, to get those patients access to that information, I think is crucial for the future of oncology. And I think you working at the NCI, more than most, know how the impact of that can help for those underrepresented patients to get more access to better treatment options and whatnot. And we can activate clinical trials as well in new models, decentralized models, adjusting time models, all those things can be leveraged by using biomarker testing in real time. Identification when the patient really needs a trial option or a medication option, because the data is telling us when to activate that in real time. Dr. Shaalan Beg: And identifying the patient for a potential clinical trial is one challenge. In oncology, given a lot of our trials, we are looking to enroll people at a specific time in their disease journey. So we call it first-line or second-line or third-line, becomes the next challenge. So just knowing someone has mutation number 1, 2, or 3 isn't enough to say they would be eligible for a second-line BRAF X, Y and Z mutation at a given trial. I've heard you talk a lot about this last-mile navigation for people once you've identified that they may be a soft match for a clinical trial. Can you talk about what you've seen in the ecosystem being developed on how AI is helping both clinics and patients navigate this last mile from the time they're identified for a clinical trial to the time they actually receive cycle 1, day 1? Dr. Arturo Loaiza-Bonilla: Yeah, absolutely. And that is such a critical point because, as you know, we have helped tons of patients getting trial options in thousands of cases. But even my own patients, I give them a report for trial options and they're like, “Okay, I still need help.” And we have been talking with ASCO, with the American Cancer Society, and many other very good teams, and what we see as an opportunity in technology here is leveraging those cancer journeys to know when the patient really has the opportunity to enroll in a trial, because this is a very dynamic environment. Not only the patient's condition changes because their cancer progresses, the hemoglobin changes, the cancer moves from one place to the other, and there's nuances in between, but also new medications are coming up, studies open and close, sites open and close.  So having this information as a hub, as what we call a command center, is the key to make this happen. And we can use the same tools that we use for Uber or for Instacart or whichever thing you want to do; it's already the same concept. When you need groceries, you don't need groceries every day. But Amazon gives you a ding that's like, “Well, I think you may be running out of milk,” because they already know how often you buy it, or just having the data behind the scenes of how typically these, in this case, patient journeys, may manifest based on the biomarker. So let's say a smoldering multiple myeloma is not the same across. One patient with biomarkers that make them very high risk, the risk of progressing to a multiple myeloma, first-line treatment-eligible patient is going to be much different than someone who has better risk cytogenetics. So using that tool to optimize the cancer journeys of those patients and being able to notify them in real time of new trial options, and also knowing when the patient really has that disease progression so there's a time of activation for trial matching again, the same way you get a credit score for buying a house, then you know exactly what options are in front of you at that very moment. And that is the last-mile component, which is going to be key. What we have seen that we feel is important to invest on, and we have invested heavily on it, is that until the patient doesn't sign the consent form for the clinical trial, that patient is completely unknown to most people. The site doesn't know them because they haven't been there, and they may be there, but they don't know about the options sometimes. But no one's going to invest in getting that patient to the finish line. There's a lot of support for patients on trials, but not before they enroll on trials. And we feel that this is a big opportunity to really exponentially grow the chances of patients enrolling in trials if we support them all the way from the very time they get diagnosed with cancer in any setting. And we can help that patient on a very unique journey to find the trial options using technology. So it's very feasible. We see it once again in many other equally complex tasks, so why not do it in oncology when we have all the bonafides across wanting to do this. Dr. Shaalan Beg: Can you give examples of where you are seeing it done outside of oncology that's a model that one can replicate? Dr. Arturo Loaiza-Bonilla: I mean, oncology is the toughest use case to crack. You have experiences with DCTs in the past and all that. So the big opportunities are for patients, for example, in psychiatry, when they need certain counseling and help. We see that also in medical devices, when people have diabetes and they really need a device specifically for that unique situation, or also for patients with cardiovascular risk that they can in real time get access to novel therapeutics. And that's how they have been able to enroll so quickly. And all these GLP-1 inhibitors, all those models are really almost completely decentralized nowadays in something that we can extrapolate for oncology once we have aligned the ecosystem to make it see them. This is something that we can really revolutionize care while we manage all the complex variables that typically come with oncology uses.  Dr. Shaalan Beg: I would imagine while you translate those learnings from outside of oncology into oncology, a lot of those processes will be human and AI combination activities. And as you learn more and more, the human component becomes a smaller fraction, and the technology and the AI becomes more of a component. Are you seeing a similar transition in the clinical trial matching space as well? Dr. Arturo Loaiza-Bonilla: Yes. So that's why people say humans are going to be replaced. They're not. Patients still want to see a human face that they recognize, they trust. Even family members of mine want to hear from me, even if they are in the top place in the world. What we can change with technology are those things that are typically just friction points. In this case, information gathering, collecting records, getting the data structured in a way that we can use it for matching effectively, knowing in real time when the patient progresses, so we can really give them the chances of knowing what's available in real time. And collecting the information from all these other stakeholders. Like, is the site open? Is the budget approved for that place? Is the insurance allowing the specific … do they have e-consent? Those things can be fully automated because they're just burdensome. They're not helping anyone. And we can really make it decentralized for e-consent, for just getting a screening. They don't need to be screened at the site for something that they're going to receive standard of care. We can really change that, and that's something that we're seeing in the space that is changing, and hopefully we can translate it fully in oncology once we are getting the word out. And I think this is a good opportunity to do so. Dr. Shaalan Beg: You talked about your dream scenario for clinical trial matching. When you think about your dream scenario as a practicing oncologist, what are the AI tools that you are most excited about making their way into the clinic, either wishful thinking or practically? Dr. Arturo Loaiza-Bonilla: I typically get feedback from all over the place on doing this, and I also have my own thoughts. But I always come to this for a reason. We all became physicians and oncologists because we like being physicians. We like to talk to patients. We want to spend the time. I tell folks in my clinic, I will see a thousand patients all the time as long as I don't have to do notes, as long as I don't have to place orders. But of course, they will have to hire 1,000 people ancillary to do all the stuff that we do.  If we can go back and spend all that time that we use on alert fatigue, on clicking, on gathering things, fighting insurance, and really helping align those incentives with clinical trials and biomarker testing and really making it a mankind or a humankind situation where we're all in this really together to solve the problem, which is cancer, that will be my dream come true. So I don't have to do anything that is clerical, that is not really helping me, but I want to use that AI to liberate me from that and also use the data that is generated for better insights. I think that I know my subject of expertise, but there's so many things happening all the time that it is hard to keep up, no matter how smart you are. If the tool can give me insights that I didn't even know, then leverage that as a CME or a board certification, that would be a dream come true. Of course, I'm just dreaming here, but it's feasible. Many of these ideas, as I mentioned, they're not new. The key thing is getting them done. The innovative part is getting stuff done, because I'm sure there's a gazillion people who have the same ideas as I did, but they just don't know whom to talk to or who is going to make it happen in reality. And that's my call to action to people: Let's work together and make this happen. Dr. Shaalan Beg: Well, Arturo, thanks a lot for sharing your insights with us today on the ASCO Daily News Podcast. Dr. Arturo Loaiza-Bonilla: Well, thank you so much for the time and looking forward to having more exchanges and conversations and seeing everyone in the field. Dr. Shaalan Beg: And thank you to our listeners for your time today. You'll find a link to the studies discussed today in the transcript of this episode. And if you value the insights that you hear on the podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:  Dr. Shaalan Beg    @ShaalanBeg Dr. Arturo Loaiza-Bonilla @DrBonillaOnc   Follow ASCO on social media: @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn     Disclosures:    Dr. Arturo Loaiza-Bonilla: Leadership: Massive Bio Stock and Other Ownership Interests: Massive Bio Consulting or Advisory Role: Massive Bio, Bayer, PSI, BrightInsight, Cardinal Health, Pfizer, Eisai, AstraZeneca, Regeneron, Verily, Medscape Speakers' Bureau: Guardant Health, Bayer, Amgen, Ipsen, AstraZeneca/Daiichi Sankyo, Natera   Dr. Shaalan Beg:    Consulting or Advisory Role: Ispen, Cancer Commons, Foundation Medicine, Genmab/Seagen    Speakers' Bureau: Sirtex    Research Funding (An Immediate Family Member): ImmuneSensor Therapeutics    Research Funding (Institution): Bristol-Myers Squibb, Tolero Pharmaceuticals, Delfi Diagnostics, Merck, Merck Serono, AstraZeneca/MedImmune

It's finally time to push the story forward and learn Ipsen's dastardly secret. Amarant proves teamwork is lame. Are we wearing the right gear? What's with the lightning sword? It's exciting to be dungeoning again. Special Guest: Spencer Crittenden.   Discord: https://discord.gg/uBw8TsBxKs Video Version at Patreon: patreon.com/nockat For T-shirts and mugs: http://etsy.com/shop/nockat For Mognet messages, email: NOCKATpodcast@gmail.com Youtube: https://www.youtube.com/@noonecanknowaboutthispodca2316 Twitter: @NOCKATpodcast

We try to finish the friendly monster quest, but can't defeat any Yans. Then we get all the stellazio and frogs we can get, before finally heading toward Ipsen's Castle. Oh yeah and we fight the monsters in the weapon shop in Treno. Special Guest: Spencer Crittenden.   Discord: https://discord.gg/uBw8TsBxKs Video Version at Patreon: patreon.com/nockat For T-shirts and mugs: http://etsy.com/shop/nockat For Mognet messages, email: NOCKATpodcast@gmail.com Youtube: https://www.youtube.com/@noonecanknowaboutthispodca2316 Twitter: @NOCKATpodcast

Building on Episode 12, which focused on primary treatment for prostate cancer, Drs. Loblaw, Lalani and Wallis move on to discuss post-op treatments, including the evolution of post-operative radiotherapy and the shift from adjuvant therapy to early salvage therapy.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: https://theviewongu.com This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Merck, Novartis, Pfizer and TerSera

Dr. Andrew Loblaw (Radiation Oncologist (Sunnybrook Research Institute), Clinician Scientist, and dual Professor in the Department of Radiation Oncology and the Institute of Health Policy Management & Evaluation at the University of Toronto) takes time out of the busy 2024 Canadian Urological Association Annual Meeting schedule to chat with Dr. Aly-Khan Lalani and Dr. Christopher Wallis. Dr. Loblaw provides an overview of how he treats his patients, including shifting to hypofractionation, brachytherapy boosts and more. Keep an eye out for Episode 13, which is the second and final part of this mini-series! This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Merck, Novartis, Pfizer and TerSera. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: https://theviewongu.com

After securing approval last week for Alzheimer's drug Kisunla, Eli Lilly was back in the news Monday with the $3.2 billion acquisition of immunology biotech Morphic Holding. This represents another deal in the lucrative immunology and inflammation (I&I) space, which saw $12.3 billion in M&A activity last year, with analysts predicting this momentum would carry over into 2024.  Investment continues to pour into another hot therapeutic space: antibody-drug conjugates (ADCs). British biopharma company Myricx Bio netted a £90 million ($115.5 million) Series A round to expand its ADC platform and advance its pipeline into the clinic. Several other pharmaceutical companies are looking to capitalize on the potential of the ADC market—which is estimated to reach nearly $30 billion by 2028—including Johnson & Johnson, Genmab and Ipsen, who have all struck M&A deals in the space this year. Still others, including Sutro Biopharma and Mersana Therapeutics, are hoping to supercharge their potential via the immune system with immunostimulatory ADCs. And GLP-1s continue to make headlines, with one study linking semaglutide to an optic nerve condition that can cause sudden vision loss, and another showing the drug class could significantly lower the risk of 10 obesity-related cancers in diabetes patients. Novo Nordisk's Wegovy has successfully expanded into China, where its patent will expire in less than two years, paving the way for biosimilar competition, and Lilly's Mounjaro elicited greater weight loss than Novo's Ozempic in a new observational study.

In this CME episode, Dr. Andrew Cutler interviews Dr. Laxman Bahroo about the current landscape of tardive dyskinesia, including screening, diagnosis, and treatment. Practical strategies based on the latest data are reviewed at length, particularly for long-term management of tardive dyskinesia.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Consider the individual patient profile and symptoms when determining a treatment plan for patients with tardive dyskinesia Integrate latest safety, efficacy, and tolerability data of VMAT2 inhibitors into decision-making processes when considering treatment options for tardive dyskinesia Evaluate practical strategies for patient follow-up and long-term VMAT2 inhibitor treatment Evaluate and integrate recent updates and advancements regarding evidence-based treatment strategies for tardive dyskinesia Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit. Estimated Time to Complete: 1 hour Released: June 26, 2024*   Expiration: June 25, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-02-TD Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hours Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEUs). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until June 25, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1.0 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Laxman B. Bahroo, DO, MS, FAAN Professor and Residency Program Director, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC Consultant/Advisor: AbbVie, Amneal, Ipsen, Kyowa Kirin, Merz, Neurocrine, Revance, Supernus Speakers Bureau: AbbVie, Acadia, Acorda, Amneal, Ipsen, Kyowa Kirin, Merz, Neurocrine, Supernus, Teva The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Meghan Grady, Brielle Calleo, and Andrea Zimmerman, EdD. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences.

Check out Nascentmc.com for medical writing assistance. visit learnAMAstyle.com for free downloads on medical writing and editing Adbry for Atopic Dermatitis The FDA has approved tralokinumab-ldrm (Adbry) as a 300 mg single-dose autoinjector for moderate-to-severe atopic dermatitis (AD) in adults, offering a more convenient delivery method. Adbry, which inhibits IL-13, was previously approved for adults in December 2021 and for pediatric patients aged 12 and older in December 2023. The approval was granted to LEO Pharma Inc.  Augtyro for NTRK Tumors The FDA has approved repotrectinib (Augtyro) for treating solid tumors with NTRK gene fusions in patients aged 12 and older, based on Phase 1/2 trials showing significant response rates in both TKI-naïve and previously treated patients. The approval was granted to Bristol Myers Squibb, with additional clinical data required to confirm safety and efficacy. Donanemab for Alzheimer's FDA advisors unanimously recommended the approval of donanemab for Alzheimer's disease, emphasizing its efficacy in slowing early-stage disease and manageable risks. Donanemab, targeting amyloid plaques, offers potential advantages over Leqembi with monthly infusions. The FDA decision is expected soon. Iqirvo for Primary Biliary Cholangitis The FDA granted accelerated approval to elafibranor (Iqirvo) for primary biliary cholangitis (PBC) to be used with ursodeoxycholic acid or as monotherapy. Elafibranor targets PPAR-α and PPAR-δ, with Phase 2 trials showing significant biochemical responses. The approval was granted to GENFIT and Ipsen.  Retevmo in Thyroid Cancer The FDA granted full approval to selpercatinib (Retevmo) for advanced or metastatic RET fusion–positive thyroid cancer in patients aged 2 years and older, based on the LIBRETTO-001 trial showing high response rates. The approval was granted to Eli Lilly and Company. OTC Continuous Glucose Monitors The FDA approved Abbott Laboratories' continuous glucose monitoring systems, Libre Rio and Lingo, for over-the-counter use. Libre Rio is for Type 2 diabetes patients not on insulin, while Lingo targets non-diabetic consumers for health improvement. These systems provide real-time glucose monitoring via a smartphone app. Check out Nascentmc.com for medical writing assistance.visit learnAMAstyle.com for free downloads on medical writing and editing  

Wael er nu for alvor kommet ind i det kriminelle miljø. Han begynder at tjene enormt mange penge - først rockeraspirant og senere som hvidvasker. Men livet i overhalingsbanen kommer med en pris, og pludselig kommer Wael i store problemer. Serien her er baseret på bogen 'Hvidvaskeren' - skrevet af Svante Karlshøj Ipsen og Wael. Hør hele afsnittet i DR Lyd.

In this debut episode of SNiPs, a special recurring segment of Fractals: Life Science Conversations, Alexander (Sandy) J.B. McEwan, MB, MSc, FRCPC, Bracken's in-house expert in nuclear medicine, returns to the audio stage. Dr. McEwan, who has served as Past President of SNMMI, Chief Medical Officer at Ariceum, and Vice President of Radiopharmaceuticals at Ipsen, brings a wealth of experience and academic knowledge. He and host Colin Miller discuss the anticipated technological advancements in the radiopharmaceutical field to take place over the next decade. Topics include the importance of dosimetry, the "external beam paradigm," treatment options, AI in clinical trials and medical imaging, and more—all in under 6 minutes. This SNiP is a small segment of a larger conversation—to learn more about the necessity of nuclear medicine, tune into Dr. Sandy McEwan's full-length episode now.

Thornton v. Ipsen Biopharmaceuticals, Inc.

Needless to say Aimee Hofmann is an INSPIRATION to many!   At 30, she suffered from the neurological condition, Transverse Myelitis, an inflammation in the spinal cord that caused complete paralysis from level T10 of the spine. After learning she would never walk again, art gave her peace during the difficult stages of loss, grief, self-reflection, and re-discovery. Art helped her emotionally heal, as well as find joy again.   Throughout the years that followed, while facing a new life with a disability, Aimee created a number of collections. Her works featured landscapes, abstract florals and swirl patterns, which have continued to evolve into deeper abstract work.   Her unique abstract art has inspired many with its vibrancy and depth, symbolizing the resilience and strength found in the journey of recovery.   Aimee is being honored on June 6th by Burke Rehabilitation Hospital with the Burke Award, their highest honor. This year's theme is the "Healing Power of the Arts," which highlights the transformative impact of the arts in rehabilitation and recovery. Burke is a nationally renowned rehabilitation hospital located in White Plains NY and Aimee's impactful artwork adorns the walls throughout Burke Rehabilitation's buildings.   Aimee joined me to share her pride in how her unexpected journey brought her to this moment and how art contributes to the rehabilitation and recovery process for patients. I asked Aimee to talk about what she does every day and how she does it.  Her most recent collections she said, express a newfound freedom that embraces the beauty of imperfections, renewal/rebirth and nostalgia and the symbolism of one's unique life journey.   “After I became paralyzed throughout the years that followed, I learned so many life lessons. I did a lot of self-reflection and self-rediscovery work. One of the things was that I learned to let go of perfectionism, and it's something that I struggled with throughout my whole life. And so, my latest work features, for example, paint in diverse textures and various consistencies, which I liberally pour and splatter all over the canvas. And this kind of embracing the beauty of imperfections, allowing the paint organically to react instead of focusing on being perfect and that is a complete reflection of my personal journey. " "And so, acquiring a disability has also helped me discover this newfound courage that was born from the realization that there is nothing to fear because I realized that the future will always be uncertain for everybody no matter what. So, this epiphany has allowed me to relinquish control over outcomes, allowing my intuition to guide the creative process instead of focusing so much on the final results, if that makes sense.”   Everything Aimee creates makes total sense. In addition to individual collectors and Burke Rehabilitation, Aimee Hofmann's work is part of corporate collections at Amazon, JPMorgan Chase & Co., HSBC, PricewaterhouseCoopers, Intuit, State Street Bank, Ipsen, Brown Advisory and Vigil Neuroscience. She has also shown at local and regional arts centers and has been a guest speaker at the Harvard Business School.   Aimee Hofmann lives with her husband and two children in Westchester County NY. She is a two-time hand-cyclist marathoner, avid swimmer, fundraiser, and guest speaker. As disabilities advocate her goal is to continue to create awareness about inclusion and fair representation for people with disabilities.    ********** About 'The Burke Award': Given by Burke Rehabilitation, it is conferred upon an individual or group who has made significant contributions to the field of rehabilitation, either through personal achievements, the development of research or the establishment of programs and facilities to assist individuals with disabilities. It recognizes strength and courage in overcoming the challenge of a disability or a significant contribution to the understanding of physical disability. It remains the highest honor bestowed by the Board of Trustees of Burke Rehabilitation Hospital.   The Burke Award Dinner is Burke's premier fundraiser, with proceeds supporting Burke's outstanding rehabilitative care services and the Healing Power of the Arts fund.   Your generous support of the 2024 Burke Award being held on June 6th will make a difference in the lives of the thousands of patients Burke serves each year.     Enjoy being inspired to learn how art heals by the fabulous Aimee Hofmann in this podcast of our live conversation on The Debbie Nigro Show. 

Pascal Prigent, the CEO of GENFIT,  a French biotech that has been working on liver diseases for about 20 years and has developed a compound called elafibranor for conditions such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and acute-on-chronic liver failure (ACLF). He highlights the high unmet medical need in ACLF, which currently has no approved treatment options and a high mortality rate. Prigent also discusses Genfit's partnership with Ipsen for the development and commercialization of elafibranor in PBC. Pascal explains, "In reality, we don't have any approved option in ACLF, which is actually quite dramatic because you have a high mortality rate. To give you a little bit of context, people are suffering from chronic liver disease, regardless of the etiology. It can be too much alcohol consumption, it could be NASH, it could be viral hepatitis. Any kind of chronic liver disease will give us all the same journey, if you will." "First, you have an injury to the liver. Then you have a progressive liver scar. You have the setup of fibrosis, that fibrosis becomes worse and worse. It becomes bridging fibrosis, but at some point, it will become cirrhosis. And that cirrhosis is first compensated, and then one day it can decompensate, and on that already failing organ, you have a precipitating factor." "That precipitating factor could be an infection, binge-drinking, or drug-induced trauma. That stress on an already sick organ will get the liver to decompensate, and that decompensation of the liver will trigger additional organ decomposition, and that's what ACLF is. It's a syndrome at the very end of chronic liver diseases." #GENFIT #LiverDisease #NASH #PBC #ACLF #LiverFailure #Hepatitis #ChronicLiverDisease #RareDisease GENFIT.com Download the transcript here

Pascal Prigent, the CEO of GENFIT,  a French biotech that has been working on liver diseases for about 20 years and has developed a compound called elafibranor for conditions such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and acute-on-chronic liver failure (ACLF). He highlights the high unmet medical need in ACLF, which currently has no approved treatment options and a high mortality rate. Prigent also discusses Genfit's partnership with Ipsen for the development and commercialization of elafibranor in PBC. Pascal explains, "In reality, we don't have any approved option in ACLF, which is actually quite dramatic because you have a high mortality rate. To give you a little bit of context, people are suffering from chronic liver disease, regardless of the etiology. It can be too much alcohol consumption, it could be NASH, it could be viral hepatitis. Any kind of chronic liver disease will give us all the same journey, if you will." "First, you have an injury to the liver. Then you have a progressive liver scar. You have the setup of fibrosis, that fibrosis becomes worse and worse. It becomes bridging fibrosis, but at some point, it will become cirrhosis. And that cirrhosis is first compensated, and then one day it can decompensate, and on that already failing organ, you have a precipitating factor." "That precipitating factor could be an infection, binge-drinking, or drug-induced trauma. That stress on an already sick organ will get the liver to decompensate, and that decompensation of the liver will trigger additional organ decomposition, and that's what ACLF is. It's a syndrome at the very end of chronic liver diseases." #GENFIT #LiverDisease #NASH #PBC #ACLF #LiverFailure #Hepatitis #ChronicLiverDisease #RareDisease GENFIT.com Listen to the podcast here

Welcome to the Transforming Medical Communications podcast brought to you by MedComms Experts. I am your host, Wesley Portegies. This podcast explores the dynamic landscape of Medical Communication strategies, innovations, and challenges. We aim to facilitate insightful conversations that contribute to advancing effective Medical Communications practices.

C dans l'air du 8 avril 2024 - Deux mois après avoir érigé la santé en priorité dans son discours de politique générale, le Premier ministre passe aux annonces. Dans un entretien à la presse régionale, le chef du gouvernement a confirmé samedi la mise en place d'ici 2025 d'une "taxe lapin" de cinq euros pour chaque rendez-vous médical non honoré. "Quand on a un rendez-vous chez le médecin et qu'on ne vient pas sans prévenir, on paie", avait prévenu Gabriel Attal en janvier dernier. Le chef du gouvernement veut ainsi responsabiliser les patients et reverser la somme au praticien concerné. Autres mesures dévoilées par le Premier ministre, la possibilité pour les pharmaciens de délivrer des antibiotiques pour les angines ou les cystites, ou encore permettre aux opticiens d'adapter des verres sans faire passer le patient par l'ophtalmologue… Le chef du gouvernement veut également doubler le nombre de médecins formés chaque année. "Il y avait 8 000 places en deuxième année de médecine en 2017, il y en aura jusqu'à 16 000 en 2027", promet-il. Des expérimentations vont également être lancées pour évaluer la possibilité de voir un kiné sans ordonnance et de prendre directement rendez-vous chez un médecin spécialiste sans avoir d'abord consulté son médecin traitant. Mais ces déclarations laissent les professionnels dubitatifs voire très en colère, à l'image de Jérôme Marty, le président du syndicat Union française pour une médecine libre. "On nous ressort encore une fois toute une série de mesures qui tiennent plus de l'incohérence que de la cohérence. Je suis inquiet. Il y a des élections qui arrivent, il faut montrer qu'on fait quelque chose, donc on bricole et on affiche", a-t-il déploré au micro d'Europe 1. Selon lui, tout le monde souffre, tous les Français ont des difficultés et le système est par terre. De son côté, le syndicat MG France a suspendu ce dimanche sa participation aux négociations avec l'Assurance maladie pour protester. Face à la dégradation des comptes de la Sécurité sociale, le gouvernement a déjà décidé de faire payer un peu plus les patients sur leur consommation de soins, en augmentant la part non remboursée par l'Assurance maladie et les complémentaires santé. Depuis dimanche, la franchise sur les médicaments et les actes paramédicaux est passé de 50 centimes à 1 euro. Celle sur les transports sanitaires est elle aussi doublée, à 4 euros. Le gouvernement a également indiqué ces dernières semaines vouloir traquer l'explosion des arrêts maladie mais également le transport sanitaire. Il a par ailleurs laissé entendre qu'il pourrait restreindre la liste des ALD (une trentaine aujourd'hui). Alors comment améliorer l'accès aux soins ? Qu'est-ce qui va changer concrètement pour les patients ? Et où en est-on dans la lutte contre les pénuries de médicaments ? Alors que les ruptures, notamment d'antibiotiques, se sont multipliées en Europe ces derniers hivers, le ministre délégué chargé de l'Industrie, a dévoilé ces derniers jours la création d'une "Alliance européenne du médicament" qui sera officialisée le 24 avril 2024. "L'idée est de concerter tous les acteurs, industriels, États membres, associations de patients - pour éviter les pénuries" a expliqué le ministre qui en a profité pour rappeler l'engagement de la France sur cette question : depuis trois ans, l'État a investi près de 1 milliard d'euros pour soutenir la production et la relocalisation de médicaments critiques. Plus récemment, 50 millions ont été injectés en vue de rapatrier 25 médicaments prioritaires. Pierre Fabre vient ainsi relocaliser en Occitanie la production d'un traitement contre le mélanome, jusque-là produit en Allemagne. Un autre laboratoire français, Ipsen, a relocalisé dans le Var la production d'un médicament contre le cancer du pancréas. La fabrication de curare, qui avait fait défaut pendant le Covid, ainsi que celle d'amoxicilline, sont aussi en cours de relocalisation. LES EXPERTS : - Gérald Kierzek - Médecin urgentiste, directeur médical – Doctissimo - Nicolas Berrod - Journaliste – Le Parisien-Aujourd'hui en France - Dominique Seux - Directeur délégué de la rédaction - Les Echos - Faïza Bossy - Médecin généraliste - Claude Rambaud (en duplex) - Juriste, spécialiste du droit médical, vice-présidente de France Assos Santé

Audio roundup of selected biopharma industry content from Scrip over the business week ended 5 April 2024. In this episode: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda. https://scrip.citeline.com/SC150062/Quick-Listen-Scrips-Five-MustKnow-Things

Ipsen Biopharmaceuticals, Inc. v. Xavier Becerra

This week, Zed and Adam continue disc 3, at long last with an airship! It's time for Ipsen's Castle. Next week they go shrine hunting.

This week, Zed and Adam continue disc 3, at long last with an airship! It's time for Ipsen's Castle. Next week they go shrine hunting.

This week, Zed and Adam continue disc 3 in the Desert Palace and Mount Gulug. Next week they head to Ipsen's Castle.

This week, Zed and Adam continue disc 3 in the Desert Palace and Mount Gulug. Next week they head to Ipsen's Castle.